Arcturus Therapeutics

Arcturus therapeutics is a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines. We have proprietary technologies, validating partnerships, and an experienced team with deep expertise in delivery and RNA-based therapeutics

Corporate Deck

LUNAR® Delivery Technology

U.S. Headquarters
Global Multicultural Team

Arcturus Therapeutics has built a multicultural team, based in San Diego, CA, USA

We have an exciting COVID-19 vaccine candidate that we hope will make a positive difference in the pandemic

See our team describe what it means for them to help get a vaccine to protect people around the world-no matter where you are from

arabic
(عربى)

chinese
(中文)

english
(British)

farsi
(فارسی)

french
(Français)

german
(deutsch)

hebrew
(עִברִית)

hindi
(हिन्दी)

italian
(italiano)

Japanese
(日本語)

korean
(한국어)

portuguese
(Português)

spanish
(español)

vietnamese
(Tiếng Việt)

COVID-19 Vaccine Using
STARR™ mRNA Technology

COVID-19 Virus

News & Events

March 4, 2013

Arcturus Therapeutics Begins Operations in Janssen Labs

May 8, 2013

Arcturus Therapeutics Announces New Appointments to its Board of Directors and Scientific Advisory Board

June 1, 2013

Arcturus Therapeutics Raises $1.3 Million in Series Seed Funding

June 3, 2013

With $1.3M in Seed Funding, Arcturus Adds to RNAi Hub in San Diego

October 1, 2020

Arcturus Therapeutics to Present at Guggenheim’s Vaccines and Infectious Diseases Conference

October 5, 2020

Arcturus Therapeutics Announces Completion of First Three Dose Escalation Cohorts in Phase 1 Study of ARCT-810, Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency

October 6, 2020

Recipharm signs agreement with Arcturus Therapeutics to support the manufacture of LUNAR®-COV19 (ARCT-021) vaccine candidate

October 30, 2020

Arcturus Therapeutics to Report Third Quarter 2020 Financial Results and Provide Corporate Update on Nov 9, 2020

November 4, 2020

Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences

November 9, 2020

Arcturus Therapeutics Announces Positive Interim ARCT-021 (LUNAR-COV19) Phase 1/2 Study Results for Both Single Shot and Prime-boost Regimens, and Up to $220 Million in Additional Financial Commitments from Singapore

November 9, 2020

Arcturus Therapeutics Announces Third Quarter 2020 Financial Results and Positive Clinical Updates for ARCT-810 Phase I Study and Additional ARCT-021 Interim Data

November 30, 2020

Arcturus Therapeutics to Present at Upcoming Investor Conference

December 7, 2020

Arcturus Therapeutics Announces Initiation of Dosing ARCT-810 in Patients with Ornithine Transcarbamylase (OTC) Deficiency

December 7, 2020

Arcturus Therapeutics Announces Proposed Public Offering of Common Stock

December 7, 2020

Arcturus Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock

December 28, 2020

Arcturus Therapeutics Received Approval from Singapore Health Sciences Authority to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate and Provides New and Updated Clinical and Preclinical Data

December 30, 2020

Arcturus Therapeutics to Advance ARCT-032, an Aerosolized LUNAR® mRNA-based Therapeutic, as a Development Candidate for Cystic Fibrosis Lung Disease

January 4, 2021

Arcturus Therapeutics Receives FDA Allowance to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate in the United States

January 6, 2021

Arcturus Therapeutics to Present at Upcoming Investor Conference

February 11, 2021

Arcturus Therapeutics to Present at Upcoming Investor Conferences

February 19, 2021

Arcturus Therapeutics to Report Fourth Quarter and Year-End 2020 Financial Results and Provide Corporate Update on March 1, 2021

February 22, 2021

Arcturus Therapeutics Acquires Exclusive License to mRNA Manufacturing Technology from Alexion Pharmaceuticals

March 1, 2021

Arcturus Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Positive Clinical Updates

March 30, 2021

Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences

https://ng459b.p3cdn2.secureserver.net/wp-content/uploads/2020/11/Arcturus_Lobby_Large.jpg?time=1749573105

https://ng459b.p3cdn2.secureserver.net/wp-content/uploads/2018/05/18arct1244fxF.jpg?time=1749573105

https://ng459b.p3cdn2.secureserver.net/wp-content/uploads/2020/11/ArcBuilding_Final.jpg?time=1749573105

https://ng459b.p3cdn2.secureserver.net/wp-content/uploads/2018/05/18arct1055fxF.jpg?time=1749573105

https://ng459b.p3cdn2.secureserver.net/wp-content/uploads/2016/05/main-visual-office-exterior.jpg?time=1749573105

https://ng459b.p3cdn2.secureserver.net/wp-content/uploads/2016/05/main-visual-office-interior-tag-line.jpg?time=1749573105

https://ng459b.p3cdn2.secureserver.net/wp-content/uploads/2020/09/20arctlab286fxFNLLo-scaled.jpg?time=1749573105

https://ng459b.p3cdn2.secureserver.net/wp-content/uploads/2020/09/20arctlab228fxFNLLo-scaled.jpg?time=1749573105

https://ng459b.p3cdn2.secureserver.net/wp-content/uploads/2020/09/20arctlab206fxFNLLo-scaled.jpg?time=1749573105

LUNAR^®-mediated delivery of RNA into cells

LUNAR^® particles associate with the cell membrane of a target cell of interest and quickly enter the cell via endocytosis.

Upon entering the cytosol, the LUNAR^® formulations then become trapped in the endosomes.

With increased acidity as the endosome ages, a pH-mediated disruption enables release of the RNA payload following rapid biodegradation of the LUNAR^®components.

Once release of the RNA into the cytosol occurs, the translational machinery can interact with the RNA and processing and/or trafficking can then take place to make functional protein.

LUNAR^® lipid mediated delivery enables delivery of RNA medicines.

March 4, 2013

May 8, 2013

June 1, 2013

June 3, 2013

October 1, 2020

October 5, 2020

October 6, 2020

October 30, 2020

November 4, 2020

November 9, 2020

November 9, 2020

November 30, 2020

December 7, 2020

December 7, 2020

December 7, 2020

December 28, 2020

December 30, 2020

January 4, 2021

January 6, 2021

February 11, 2021

February 19, 2021

February 22, 2021

March 1, 2021

March 30, 2021

LUNAR®-mediated delivery of RNA into cells

LUNAR^®-mediated delivery of RNA into cells